A kidney transplant is one of the most life-changing procedures in modern medicine. For the thousands of patients living with end-stage renal disease, it represents the possibility of a longer, healthier life — free from the constraints of dialysis. But before a single incision is made, both the recipient and the donor must undergo a thorough series of medical tests. These evaluations are not mere formalities. They are critical safeguards that help transplant teams determine compatibility, identify risks, and set the stage for a successful surgery.

This guide walks you through each test — one by one — for both the recipient and the donor. We also cover what changes for patients who require plasmapheresis before surgery, and explain the vital role of PRA testing in determining transplant eligibility.

Tests for the Kidney Transplant Recipient

Blood Group (ABO) Typing

The very first step in any transplant evaluation is determining the recipient’s blood group. ABO compatibility between donor and recipient is fundamental. Mismatched blood types can trigger an acute immune rejection response, which can be life-threatening. The transplant team will confirm the recipient’s ABO type and cross-reference it with that of the potential donor before proceeding with any further testing.

Tissue Typing (HLA Typing)

Human Leukocyte Antigen (HLA) typing identifies the specific proteins on the surface of the recipient’s cells. The immune system uses these markers to distinguish between “self” and “foreign” tissue. The closer the HLA match between donor and recipient, the lower the risk of rejection. A blood sample is drawn and sent to a specialist laboratory, where the HLA profile is mapped across several antigens — typically HLA-A, HLA-B, and HLA-DR.

Panel Reactive Antibody (PRA) Test

The PRA test is one of the most important immunological assessments a transplant recipient will undergo. It measures the percentage of antibodies in the recipient’s blood that react against a random panel of donor cells. In essence, it tells the transplant team how “sensitised” the recipient’s immune system is to foreign tissue.

Why does the PRA percentage matter?

A PRA result is expressed as a percentage. A recipient with a PRA of 0% has no detectable antibodies against the panel, meaning they are unsensitised and generally considered straightforward candidates for transplant. Conversely, a PRA of 80% means the recipient’s immune system reacts against 80% of the donor population — making it significantly harder to find a compatible donor and raising the risk of rejection.

• PRA below 20%: Considered low sensitisation. Most transplant centres proceed with standard protocols.
• PRA between 20–80%: Moderate sensitisation. Additional compatibility testing (such as a crossmatch) is essential before proceeding.
• PRA above 80%: Highly sensitised. These patients face the greatest challenge in finding a suitable donor. In many cases, they must undergo desensitisation treatment — including plasmapheresis — before surgery can take place.

The PRA test is typically repeated at regular intervals while the patient is on the waiting list, as sensitisation levels can change over time — particularly following blood transfusions, pregnancies, or previous transplants.

Crossmatch Test

Even when HLA typing looks promising, a final crossmatch test is performed just before surgery. A sample of the recipient’s blood is mixed directly with the donor’s cells. If the recipient’s antibodies attack the donor’s cells, the crossmatch is considered “positive” — and in most cases, the transplant will not proceed. A “negative” crossmatch is the green light that transplant teams need to move forward.

Complete Blood Count (CBC) and Biochemistry Panel

The Complete Blood Count (CBC) and biochemistry panel together form the most wide-ranging blood assessment a recipient will undergo. They give the transplant team a clear picture of the patient’s overall health and flag any conditions that must be addressed before surgery can safely proceed.

Complete Blood Count (CBC)

The CBC examines the three main cellular components of blood:

• Haemoglobin and red blood cells: Anaemia is almost universal in patients with chronic kidney disease. The kidneys produce a hormone called erythropoietin, which stimulates red blood cell production. When the kidneys fail, erythropoietin output drops — and so does haemoglobin. Transplant teams look closely at haemoglobin levels because severe anaemia increases surgical risk, impairs wound healing, and may require pre-operative treatment with erythropoietin injections or iron supplementation. A haemoglobin level below 80–90 g/L is generally flagged for intervention before surgery.
• White blood cells (WBC): The white cell count and differential — which breaks down the count into neutrophils, lymphocytes, monocytes, eosinophils, and basophils — helps the team identify active infection, immune system disorders, or haematological conditions. An elevated neutrophil count, for instance, can indicate bacterial infection; a raised eosinophil count may point to a parasitic infection or allergic process. Any active infection must be fully resolved before transplant surgery proceeds.
• Platelets: Platelets are essential for normal blood clotting. Chronic kidney disease can interfere with platelet function even when the count appears normal — a condition known as uraemic platelet dysfunction. Both a low platelet count (thrombocytopaenia) and impaired platelet function increase the risk of excessive bleeding during and after surgery. The transplant team will assess platelet count alongside clotting studies to build a complete picture of the recipient’s bleeding risk.

Biochemistry Panel

The biochemistry panel covers a broad range of markers across several organ systems:

• Kidney function markers — Creatinine, Urea, and eGFR: Serum creatinine and blood urea nitrogen (BUN) are waste products that healthy kidneys filter out. In renal failure, these accumulate. Monitoring these markers helps the team document baseline function and assess the severity of disease. The estimated Glomerular Filtration Rate (eGFR), calculated from creatinine alongside the patient’s age, sex, and body size, gives the most precise indication of remaining kidney function.
• Electrolytes — Sodium, Potassium, Bicarbonate, and Phosphate: Electrolyte imbalances are extremely common in end-stage renal disease. Hyperkalaemia (elevated potassium) is particularly dangerous — it can trigger life-threatening cardiac arrhythmias if not controlled before surgery. Sodium and bicarbonate levels reflect the body’s fluid and acid-base balance. Phosphate tends to accumulate as kidney function declines and must be managed to protect cardiovascular and bone health. All electrolyte levels must fall within safe ranges before the patient is cleared for surgery.
• Calcium: Chronic kidney disease disrupts calcium and phosphate metabolism, often causing secondary hyperparathyroidism. Low calcium (hypocalcaemia) can affect muscle function, including the heart. Elevated or suppressed calcium levels may indicate the need for treatment before proceeding.
• Liver function tests (LFTs): These include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin, and albumin. The liver plays a central role in metabolising the immunosuppressant drugs the patient will take for life after transplant. Any pre-existing liver disease — including hepatitis-related liver damage — must be identified and accounted for. Albumin, in particular, is a marker of nutritional status; low albumin is associated with poorer surgical outcomes and slower recovery.
• Blood glucose and HbA1c: Diabetes is one of the leading causes of kidney failure and is common among transplant candidates. Pre-operative blood glucose is measured to assess diabetic control at the time of testing. HbA1c — a measure of average blood sugar over the preceding two to three months — gives the team a longer-term view. Poorly controlled diabetes increases the risk of post-operative infection, delayed healing, and cardiovascular complications. It also affects the dosing of certain immunosuppressants. The team will want glucose levels optimised before proceeding.
• Uric acid: Elevated uric acid (hyperuricaemia) is common in chronic kidney disease and can worsen after transplant due to the effects of certain immunosuppressive medications. Baseline levels are recorded to guide post-operative management.
• Coagulation studies — PT, aPTT, and INR: While not always grouped with the standard biochemistry panel, clotting studies are an essential part of pre-operative blood work. Prothrombin time (PT), expressed as the International Normalised Ratio (INR), and activated partial thromboplastin time (aPTT) assess the blood’s ability to clot through different pathways. Uraemia can impair platelet function independently of clotting factor levels, so even a patient with a normal INR may have a prolonged bleeding time. Where concerns exist, fibrinogen levels may also be measured.

Together, these tests do not simply confirm that a patient is unwell — they quantify exactly how unwell they are, identify which problems need to be corrected before surgery, and give the surgical and anaesthetic team the information they need to plan a safe procedure.

Urine Tests

If the recipient still produces urine, a urinalysis and urine culture will be conducted to rule out active urinary tract infections. A 24-hour urine collection may also be requested to measure residual kidney function.

Cardiac Evaluation

Patients with chronic kidney disease are at significantly elevated risk of cardiovascular disease. Prior to transplant, recipients typically undergo:

• Electrocardiogram (ECG): To assess baseline heart rhythm and detect any arrhythmias.
• Echocardiogram: An ultrasound of the heart that evaluates structural integrity, valve function, and the ejection fraction (a measure of how efficiently the heart pumps blood).
• Stress Test or Coronary Angiography: For older recipients or those with known cardiac risk factors, a stress test — or in some cases a coronary angiogram — may be required to rule out significant coronary artery disease.

Chest X-Ray and Pulmonary Function

A chest X-ray is standard practice to evaluate the lungs and heart size. If the patient has a history of respiratory illness, pulmonary function tests may also be ordered to ensure they are fit for general anaesthesia.

Infection Screening — A Detailed Breakdown

Rather than a blanket infection screen, transplant programmes conduct highly specific checks across multiple systems. Here is what recipients can expect:

Dental Examination
Any active dental infection — including abscessed teeth, periodontal disease, or untreated cavities — must be identified and treated before surgery. Dental bacteria can enter the bloodstream during or after surgery and cause serious systemic infections in an immunosuppressed patient. Recipients must visit a dentist and obtain written clearance before transplant approval is granted.

Ear, Nose, and Throat (ENT) Assessment
Chronic sinusitis or tonsillar infections can become problematic once the recipient begins immunosuppressive therapy. An ENT review may be requested, particularly if the patient reports recurrent sinus or throat infections.

Gynaecological Screening (for female recipients)
Women are required to undergo a pelvic examination and a cervical smear (Pap test) to rule out any active infection or pre-cancerous changes. A mammogram may also be requested depending on the patient’s age and risk profile.

Skin Examination
A dermatological assessment is sometimes requested to identify any open wounds, skin infections, or suspicious lesions that could pose a post-operative risk.

Viral Serology Panel
Recipients are tested for a range of viruses, including:

• Hepatitis B and C: Active hepatitis must be managed before transplant.
• HIV: A positive HIV diagnosis is no longer an automatic contraindication in many centres, but it must be disclosed and managed.
• Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV): These latent viruses can reactivate dangerously under immunosuppression.
• Tuberculosis (TB): A tuberculin skin test or IGRA (Interferon-Gamma Release Assay) blood test is used to check for latent TB.

Special Considerations: Recipients Requiring Plasmapheresis

Plasmapheresis — also known as therapeutic plasma exchange — is a procedure that filters the blood to remove harmful antibodies. It is most commonly used in highly sensitised recipients (typically those with a PRA above 80%) or in cases where the donor-recipient crossmatch is positive but the transplant team wishes to proceed.

How do the blood tests differ for these patients?

For recipients undergoing plasmapheresis, the standard blood tests are still required — but they are conducted with far greater frequency and at very specific intervals. Here is what changes:

• PRA Testing: In standard recipients, PRA is measured every few months. In patients undergoing plasmapheresis, PRA levels are monitored before each session, immediately after each session, and again in the days following treatment. The goal is to reduce PRA to an acceptable threshold — often below 30–50%, depending on the transplant centre’s protocol — before surgery is attempted.
• Immunoglobulin Levels: Since plasmapheresis removes proteins from the blood — including immunoglobulins — the patient’s immunoglobulin G (IgG) levels must be monitored closely. If levels fall too low, intravenous immunoglobulin (IVIG) therapy may be administered.
• Clotting Profile: Plasmapheresis removes clotting factors alongside antibodies. Therefore, tests such as prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen are measured regularly to ensure the patient is not at risk of excessive bleeding during surgery.
• Albumin and Total Protein: These markers drop during plasmapheresis and are monitored to ensure the patient’s nutritional and protein status remains stable.
• Crossmatch Testing: Following each round of plasmapheresis, a fresh crossmatch test is performed to determine whether the treatment has sufficiently reduced the recipient’s antibody burden.

Tests for the Kidney Donor

Blood Group and HLA Typing

Exactly as with the recipient, the donor’s ABO blood group and HLA profile are established early in the evaluation process. This allows the transplant team to assess compatibility and predict the likelihood of rejection.

Complete Blood Count (CBC) and Biochemistry

Because the donor is an otherwise healthy individual undergoing a major operation by choice — not medical necessity — the pre-operative blood work must clear an exceptionally high bar. Every marker must fall within acceptable ranges before donation can proceed. The following tests form the core of this assessment.

Complete Blood Count (CBC)

The CBC examines the three main cellular components of the donor’s blood:

• Haemoglobin and red blood cells: Unlike transplant recipients, living donors are not expected to be anaemic. A normal haemoglobin level confirms the donor can tolerate the blood loss that occurs during nephrectomy (surgical removal of the kidney) without requiring transfusion. Low haemoglobin would need to be investigated and corrected before surgery is approved.
• White blood cells (WBC) and differential: The white cell count — broken down into neutrophils, lymphocytes, monocytes, eosinophils, and basophils — is used to rule out active infection or undiagnosed haematological conditions. Donation cannot proceed in the presence of any active infection. An abnormal differential may prompt further investigation before the team can proceed.
• Platelets: A normal platelet count is essential to confirm the donor’s ability to clot effectively during and after surgery. Thrombocytopaenia (a low platelet count) would represent a significant surgical risk and would need to be investigated. Platelet count is reviewed alongside coagulation studies to give a complete picture of bleeding risk.

Biochemistry Panel

• Kidney function markers — Creatinine, Urea, and eGFR: This is arguably the most critical component of the donor’s blood panel. Serum creatinine and blood urea nitrogen (BUN) must fall firmly within the normal range, as elevated levels indicate compromised kidney function. The estimated Glomerular Filtration Rate (eGFR), calculated from creatinine in conjunction with the donor’s age, sex, and body size, is used to assess how well both kidneys are currently functioning. Since the donor will live with only one kidney after surgery, the transplant team must be confident that the remaining kidney alone can sustain full renal function long-term. Most transplant programmes require an eGFR of at least 80 ml/min/1.73m² — though thresholds vary by centre — to ensure the donor is not placed at risk of future kidney insufficiency.
• Electrolytes — Sodium, Potassium, and Bicarbonate: Electrolyte levels are checked to confirm normal metabolic function. A healthy donor should have balanced electrolyte levels without intervention. Any significant abnormality — particularly hyperkalaemia (elevated potassium) — would raise concerns about underlying renal or adrenal pathology and would warrant further investigation before donation can be approved.
• Calcium and Phosphate: These markers are assessed to rule out parathyroid disorders, metabolic bone disease, or hidden kidney dysfunction. Abnormal calcium or phosphate in an otherwise apparently healthy donor may indicate an undiagnosed condition that could worsen after loss of one kidney.
• Liver function tests (LFTs): A full liver panel — including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, and albumin — is performed to confirm the donor has no active liver disease. While liver health does not directly affect kidney donation, abnormal LFTs may signal underlying conditions such as viral hepatitis or fatty liver disease that have implications for the donor’s overall fitness for surgery. Albumin is also a useful marker of nutritional status; a well-nourished donor with normal albumin is at lower risk of surgical complications and slower wound healing.
• Blood glucose and HbA1c: Undiagnosed or poorly controlled diabetes is a contraindication to kidney donation. Diabetes causes progressive kidney damage — donating a kidney would accelerate that process and place the donor at serious long-term risk. Fasting blood glucose is measured to assess current metabolic status, while HbA1c provides a longer-term picture of blood sugar control over the preceding two to three months. Both must be within normal limits for donation to proceed.
• Uric acid: Baseline uric acid levels are recorded. Hyperuricaemia (elevated uric acid) can be a sign of early kidney dysfunction and may also predict a higher risk of gout or kidney stone formation after the donor loses one kidney. Elevated levels prompt further evaluation before clearance is granted.
• Lipid profile — Total cholesterol, LDL, HDL, and Triglycerides: A fasting lipid panel is typically included in the donor’s blood work. Significant dyslipidaemia — particularly elevated LDL or triglycerides alongside low HDL — is associated with increased cardiovascular risk and may indicate metabolic syndrome. Since the remaining kidney will be under slightly greater workload after donation, the team must be confident the donor’s long-term cardiovascular health is not already compromised.
• Coagulation studies — PT, INR, and aPTT: Prothrombin time (PT), expressed as the International Normalised Ratio (INR), and activated partial thromboplastin time (aPTT) are measured to assess the blood’s ability to clot via both the extrinsic and intrinsic coagulation pathways. Any coagulopathy — whether due to liver disease, a clotting factor deficiency, or medication — must be identified and managed before surgery. In some cases, fibrinogen levels are also measured.
• Thyroid function (TSH): Some transplant programmes include a thyroid-stimulating hormone (TSH) measurement as part of the routine donor screen. Hypothyroidism or hyperthyroidism, if uncontrolled, can affect surgical risk and recovery. Identifying and treating thyroid dysfunction before surgery reduces the likelihood of complications.

Together, these blood tests do not simply confirm that the donor appears healthy — they verify it at a biochemical level. Every marker forms part of a detailed safety net designed to protect both the donor and the recipient, ensuring that donation is the right course of action for both parties before surgery is allowed to proceed.

24-Hour Urine Collection and GFR Assessment

A 24-hour urine collection is used to calculate the donor’s glomerular filtration rate (GFR) — a precise measure of kidney function. Since the donor will be giving up one kidney, the transplant team must confirm that the remaining kidney is healthy enough to sustain normal life. A GFR above 80 ml/min/1.73m² is generally considered acceptable, though precise thresholds vary between centres.

CT Angiography

CT angiography is one of the most important imaging studies performed on a living kidney donor. This scan uses contrast dye injected into the bloodstream to produce detailed, three-dimensional images of the blood vessels supplying the kidneys — specifically the renal arteries and veins.

The transplant surgeon relies on these images to:

• Identify the number and anatomy of renal arteries on each side (some people have two or more arteries supplying one kidney, which complicates surgery)
• Assess the length and course of the renal veins
• Detect any vascular abnormalities such as aneurysms or stenosis
• Decide which kidney to remove — typically the one with simpler vascular anatomy, to minimise surgical risk to the donor

CT angiography also provides detailed imaging of the kidney parenchyma itself, allowing radiologists to detect cysts, tumours, calculi (stones), or structural anomalies that could disqualify a kidney from donation.

Abdomen and Pelvis Sonography (Ultrasound)

An abdominal and pelvic ultrasound is typically performed alongside — or before — the CT angiography. This non-invasive imaging study allows the transplant team to:

• Measure the size of both kidneys (kidneys must be of adequate size and symmetrical development)
• Detect the presence of renal cysts, using the Bosniak classification system to determine whether any cysts pose a malignancy risk
• Identify kidney stones, even small ones that may not cause symptoms but could complicate the transplanted kidney’s function
• Assess the collecting system for any signs of obstruction or dilation (hydronephrosis)
• Examine the abdominal organs — including the liver, spleen, pancreas, and gallbladder — for any incidental findings that might affect the donor’s candidacy

If any abnormalities are detected on ultrasound, further imaging (such as MRI) may be requested before a final decision is made.

Cardiac and Pulmonary Evaluation

Just like the recipient, the donor must be fit for general anaesthesia. An ECG is performed to assess cardiac rhythm, and a chest X-ray is taken to evaluate the lungs. For donors over 50 or those with risk factors such as hypertension or obesity, an echocardiogram or stress test may also be requested.

Infection Screening for Donors

Donors undergo a similarly comprehensive infection screen to the recipient. This includes:

• Dental clearance: Active dental infections must be treated before donation proceeds.
• Viral serology: Testing for Hepatitis B, Hepatitis C, HIV, CMV, and EBV is mandatory. In some cases, a donor who is CMV-positive may still donate to a CMV-positive recipient, but a CMV-positive donor giving to a CMV-negative recipient requires careful management post-transplant.
• Tuberculosis screening: A TB skin test or IGRA blood test is standard.
• Urinalysis and urine culture: To confirm the donor has no active urinary tract infection.

Psychological and Social Evaluation

Living kidney donation carries emotional as well as physical weight. Donors are assessed by a psychologist or transplant social worker to confirm that their decision is voluntary, fully informed, and free from coercion. This is a non-negotiable part of the evaluation process.

Lab Abbreviation Glossary

Medical reports and lab results are filled with abbreviations that can feel like a foreign language. The table below explains every acronym used throughout this guide in plain terms, so you can read your results — or your loved one’s results — with confidence. Whether you’re a recipient, a donor, or a family member trying to make sense of it all, this quick-reference glossary is here to help.

• CBC (Complete Blood Count) — A test that measures all three types of blood cells: red cells, white cells, and platelets. It gives a broad picture of your overall blood health.
• ABO (ABO Blood Group System) — The system used to classify your blood type as A, B, AB, or O. Donor and recipient must be compatible to avoid rejection.
• HLA (Human Leukocyte Antigen) — Proteins on the surface of your cells that the immune system uses to tell “self” from “foreign.” The closer the HLA match, the lower the rejection risk.
• PRA (Panel Reactive Antibody) — A percentage that shows how sensitised your immune system is to foreign tissue. A higher percentage means it is harder to find a compatible donor.
• WBC (White Blood Cell Count) — Measures the immune cells in your blood. An abnormal count can signal infection, inflammation, or a blood disorder.
• eGFR (Estimated Glomerular Filtration Rate) — The best single measure of how well your kidneys are filtering waste from your blood. Calculated using creatinine, age, sex, and body size.
• BUN (Blood Urea Nitrogen) — A waste product that healthy kidneys filter out. High BUN levels indicate the kidneys are not working properly.
• LFTs (Liver Function Tests) — A group of blood tests that check how well the liver is working. Important because the liver processes the immunosuppressant drugs taken after transplant.
• ALT (Alanine Aminotransferase) — A liver enzyme. Elevated levels can indicate liver cell damage or disease.
• AST (Aspartate Aminotransferase) — Another liver enzyme, also found in muscle. High levels may point to liver or muscle injury.
• ALP (Alkaline Phosphatase) — An enzyme linked to the liver and bones. Raised levels can indicate bile duct problems or bone disease.
• GGT (Gamma-Glutamyl Transferase) — A liver enzyme that is often elevated in bile duct disorders or with alcohol-related liver damage.
• HbA1c (Glycated Haemoglobin) — Reflects your average blood sugar level over the past two to three months. Used to assess how well diabetes is controlled.
• PT (Prothrombin Time) — Measures how quickly your blood clots via one of the two main clotting pathways. A prolonged PT indicates a higher bleeding risk.
• INR (International Normalised Ratio) — A standardised way of expressing prothrombin time, used consistently across different laboratories. A higher INR means slower clotting.
• aPTT (Activated Partial Thromboplastin Time) — Measures clotting speed via the second main pathway. Used alongside PT to build a full picture of clotting ability.
• IgG (Immunoglobulin G) — The most common antibody protein in the blood. Monitored closely in patients undergoing plasmapheresis, as levels can drop significantly.
• IVIG (Intravenous Immunoglobulin) — A treatment given through a drip to replace antibodies when IgG levels fall too low, often used alongside plasmapheresis.
• CMV (Cytomegalovirus) — A common virus that lies dormant in many people. It can reactivate dangerously once a transplant recipient begins immunosuppressive therapy.
• EBV (Epstein-Barr Virus) — The virus that causes glandular fever. Like CMV, it can reactivate under immunosuppression and cause serious complications.
• HIV (Human Immunodeficiency Virus) — A virus that weakens the immune system. All donors and recipients are screened; a positive result does not automatically rule out transplant in many centres.
• TB (Tuberculosis) — A bacterial infection that can lie dormant for years. Detected using a skin test or an IGRA blood test; latent TB must be treated before transplant proceeds.

Frequently Asked Questions: Kidney Transplant Tests for Recipients and Donors

Why do both the donor and the recipient need so many tests before surgery? A kidney transplant is one of the most complex surgical procedures in medicine — and the sheer number of pre-operative tests reflects that complexity. For the recipient, the tests serve two purposes: confirming that the patient is medically fit enough to survive a major operation, and ensuring that their immune system will not reject the donor kidney. For the donor, the stakes are equally high. This is a healthy person choosing to undergo surgery voluntarily, so the transplant team has a duty to verify — at a biochemical level — that donation will not put their long-term health at risk. Beyond individual health, many of the tests are about compatibility: blood group typing, HLA matching, and the crossmatch test all determine whether donor and recipient are a safe pair. A mismatch in any one of these areas can lead to acute rejection, which can be life-threatening. Put simply, the testing process is not bureaucratic box-ticking — it is the foundation upon which a safe, successful transplant is built.

Do abnormal blood test results always delay kidney transplant surgery? Not necessarily — it depends on which result is abnormal, how significant the deviation is, and whether the underlying issue can be corrected quickly. Some abnormalities, such as mild anaemia or slightly elevated blood glucose, can often be managed in the weeks leading up to surgery without pushing back the transplant date significantly. Others, such as a positive crossmatch, an active infection, or uncontrolled hyperkalaemia, will delay surgery until the issue is fully resolved — because proceeding without doing so would place the patient at serious risk. In some cases, an abnormal result prompts further investigation rather than an immediate delay; for instance, an unexpected finding on a urine culture may simply require a short course of antibiotics before surgery can proceed. The transplant team will always weigh the urgency of the recipient’s condition against the risks posed by the abnormal result. If a patient is deteriorating rapidly on dialysis, the team may accept a slightly imperfect result and manage it peri-operatively, rather than waiting for everything to be perfect. The key takeaway is this: an abnormal result is a flag, not necessarily a barrier — and your transplant team will discuss the implications with you directly.

How often do PRA and crossmatch tests need to be repeated? The answer varies depending on the recipient’s sensitisation level and how close they are to surgery. For most recipients on the transplant waiting list, PRA testing is carried out every three to six months. However, this frequency increases significantly if the recipient undergoes a blood transfusion, a failed previous transplant, or a pregnancy — all of which can raise sensitisation levels and shift the PRA result considerably. For highly sensitised patients undergoing plasmapheresis, PRA is monitored before and after every treatment session, sometimes weekly or even more frequently, until levels fall to an acceptable threshold. The crossmatch test, by contrast, is performed as a final check immediately before surgery — typically within 48 hours of the planned operation — to confirm that the recipient has not developed new antibodies against the specific donor since the last round of testing. In some cases, a virtual crossmatch may be performed in advance using stored HLA antibody data, but a physical crossmatch using actual donor and recipient blood samples is still required before the transplant team gives the final green light. If a patient’s condition changes — for instance, if they receive a blood transfusion during a hospital admission — the transplant team may request an unscheduled PRA test to update their profile before proceeding.

Do living kidney donors need the same blood tests as transplant recipients? There is significant overlap, but the two panels are not identical — and the reasons behind each test can differ considerably. Both donors and recipients undergo ABO blood group typing, HLA tissue typing, a full CBC, a comprehensive biochemistry panel, liver function tests, viral serology, and coagulation studies. However, the purpose behind these tests shifts depending on which side of the operating table the person is on. For the recipient, many of the blood tests are about identifying disease, managing existing complications of kidney failure — such as anaemia, hyperkalaemia, and uraemic platelet dysfunction — and assessing immune sensitisation through PRA and crossmatch testing. For the donor, who is expected to be in good health, the same tests are used to verify that health rather than manage illness. The donor’s kidney function markers, in particular, are held to a stricter standard — eGFR must typically exceed 80 ml/min/1.73m² to ensure the remaining kidney alone can sustain normal life after donation. There are also tests that apply exclusively to donors, such as CT angiography and a detailed lipid profile, and tests more relevant to recipients, such as PRA monitoring and the crossmatch. In short, while the two lists look similar on paper, they serve distinct clinical purposes — and understanding that distinction can help both donors and recipients feel more confident as they navigate the pre-transplant evaluation process.

The Road to Surgery

The volume and depth of pre-transplant testing can feel overwhelming — but each test serves a distinct and vital purpose. Together, they form a comprehensive picture of both the donor’s and recipient’s health, allowing the transplant team to minimise risk, optimise compatibility, and give the surgery the best possible chance of success.

If you or a loved one is navigating the kidney transplant process, here is what to do next:

For recipients: Start by speaking with your nephrologist about your current PRA status and whether you are ready to begin the full pre-transplant evaluation. Once cleared, the Medipars team can help coordinate your testing, match you with a suitable donor, and manage every step of your care — from initial consultation through to post-operative follow-up.

For potential donors: If you are considering donating a kidney to a family member or loved one, the first step is a confidential health assessment to determine whether you are a suitable candidate. Medipars will guide you through the full donor evaluation process, ensure your long-term wellbeing is protected, and support you at every stage of the journey.

As a leading medical tourism facilitator with extensive experience coordinating kidney transplants in Iran, Medipars supports patients and their families every step of the way. Get in touch today to find out how we can help you take the next step.

Reviewed by Dr. Ataei Pour, Nephrologist and Kidney Transplant Specialist — Last reviewed: August 2026 — This article is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified medical professional regarding your individual health circumstances. If you are considering kidney transplant evaluation in Iran, contact the Medipars team for personalised, expert guidance through every stage of your journey.